| |
|
|
|
|
| Slide Lecture Programs |
| 2006 Core Curriculum |
| Antiplatelet Interventions in ACS |
March 10, 2006
|
| II: |
Thrombus Susceptibility and the Vulnerable Plaque
- As the platelet emerged as a pivotal entity in CVD, a number of antithrombotic agents have been developed that prevent platelet aggregation and activation at critical points in the thrombotic cascade, and they have been shown in large-scale randomized trials to improve patient outcomes in ACS and PCI.
- The antiplatelet agents include aspirin, the thienopyridine clopidogrel, and its predecessor ticlopidine.
- Intravenous GP IIb/IIIa inhibitors block the final common pathway of platelet activation and aggregation, and the GP IIb/IIIa receptor is therefore an attractive therapeutic target. GP IIb/IIIa inhibitors include abciximab, tirofiban, and eptifibatide.
- Thrombin is blocked by unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), notably enoxaparin, and by direct thrombin inhibitors (eg, bivalirudin).
|
|
|
Resources